Keith Regnante

Keith Regnante

Chief Financial OfficeratKeros Therapeutics· In proxies 2021–2025

Pay in FY2025-51% from the year before · Keros Therapeutics stock +28.6% the same year

Keith Regnante was paid $1.1M in FY2025 (Dec), down 51%. Keros Therapeutics stock rose 28.6% that year.

Pay$100 in the stock at the end of FY20 → $35
Pay is from the Summary Compensation Table of each Keros Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Keros TherapeuticsPublic company · 5 yr
    • Chief Financial Officer2021 – Present · 5 yrStock in role -85%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?